SCYNEXIS, Inc. Reports First Quarter 2015 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SCYNEXIS, Inc. Reports First Quarter 2015 Financial Results

RESEARCH TRIANGLE PARK, N.C., May 15, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq: SCYX ) today reported financial results for the first quarter of 2015.

"We are in a strong financial position following the successful completion of our follow-on public offering in April 2015, which resulted in net proceeds of $37.8 million," said Marco Taglietti, SCYNEXIS' Chief Executive Officer. "These cash resources are projected to allow us to progress our lead product candidate, SCY-078, through several key milestones, bringing us closer to providing a new treatment option to patients with life-threatening invasive fungal infections."

Recent Developments

  • SCYNEXIS successfully completed a follow-on public offering in April 2015, selling approximately 5.4 million shares of our common stock at a public offering price of $7.70 per share, providing net proceeds of approximately $37.8 million after underwriting discounts and commissions and estimated offering expenses;
  • David Angulo, M.D., has accepted an offer to join SCYNEXIS as Chief Medical Officer, effective June 1, 2015; and
  • Charles F. Osborne, Jr., our current Chief Financial Officer, is resigning from SCYNEXIS effective June 30, 2015, and we have commenced a search for a new chief financial officer.

SCY-078 Update

  • Implemented protocol amendments to our Phase 2 study of oral SCY-078 to facilitate patient enrollment;
  • Top line results of our Phase 2 study are expected in the first half of 2016 as planned; and
  • IND-enabling toxicology studies are being completed in support of the IND for the Phase 1 Program of an IV formulation of SCY-078 which is planned to begin in the second half of 2015.

First Quarter 2015 Financial Results

SCYNEXIS reported a net loss of $6.4 million for the first quarter of 2015, compared to net income of $0.4 million for the first quarter of 2014. The net loss in the first quarter of 2015 was primarily due to costs associated with the development of SCY-078 and public company operating expenses. The net income for the first quarter of 2014 was primarily due to a gain of $2.8 million from a derivative fair value adjustment, largely offset by an operating loss of $1.8 million. Diluted net loss attributable to common stockholders for the first quarter of 2015 was $6.4 million, or $0.75 per diluted common share. This compares to diluted net loss attributable to common stockholders for the first quarter of 2014 of $1.2 million, or $6.57 per diluted common share. 1

Research and development expenses increased to $4.2 million in the first quarter of 2015, compared to $1.3 million in the first quarter of 2014. The increase of $2.9 million was primarily due to increased costs associated with the SCY-078 Phase 2 clinical trial and the preclinical development of intravenous SCY-078, as well as increased employee compensation costs.

Cash and cash equivalents totaled $27.6 million as of March 31, 2015.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com .

Forward Looking Statement

Statements contained in this press release regarding matters that are not historical facts, including those statements regarding any future performance of SCYNEXIS's product candidates, the potential of SCY-078 to treat invasive fungal infections, the therapeutic and commercial potential of SCY-078, and the anticipated timing and therapeutic and commercial potential of the product candidates of SCYNEXIS are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Additional risks related to SCYNEXIS are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

1 The issuance of common stock and the conversion of our outstanding shares of preferred stock during our initial public offering in May 2014 caused a significant increase in common shares outstanding and has impacted the comparability of our net loss per share calculations between first quarter of 2015 and first quarter of 2014 periods.

 
 
SCYNEXIS, INC.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)  
 
  Three months ended March 31,
  2015 2014
Revenue — related party $ 987 $ 1,822
Revenue 2,310 2,883
Total revenue 3,297 4,705
Cost of revenue 3,231 3,960
Gross profit 66 745
Operating expenses:    
Research and development 4,218 1,320
Selling, general and administrative 2,233 1,206
Total operating expenses 6,451 2,526
Loss from operations (6,385) (1,781)
Other (income) expense:    
Amortization of deferred financing costs and debt discount — 536
Interest (income) expense (1) 44
Derivative fair value adjustment — (2,783)
Other expense — 10
Total other (income) expense: (1) (2,193)
Net (loss) income $ (6,384) $ 412
Deemed dividend for beneficial conversion feature on Series D-2 preferred stock — (909)
Deemed dividend for antidilution adjustments to convertible preferred stock — (214)
Accretion of convertible preferred stock — (510)
Net loss attributable to common stockholders - basic $ (6,384) $ (1,221)
Derivative fair value adjustment — (2,783)
Net loss attributable to common stockholders - diluted (6,384) (4,004)
Net loss per share attributable to common stockholders:    
Basic $ (0.75) $ (3.65)
Diluted $ (0.75) $ (6.57)
Weighted average common shares outstanding:    
Basic 8,516,467 334,086
Diluted 8,516,467 609,074
     
     
SCYNEXIS, INC.
BALANCE SHEET DATA
(in thousands)
     
  March 31, 2015 (Unaudited) December 31, 2014
Cash and cash equivalents $ 27,620 $ 32,243
Total current assets 29,830 34,736
Total assets 34,857 39,672
Total current liabilities 5,132 3,801
Total liabilities 7,419 6,241
Total stockholders' equity 27,438 33,431
Total liabilities and stockholders' equity 34,857 39,672

Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781-235-3060 Investor Relations Jillian Connell The Trout Group LLC Tel: 646.378.2956 SCYNEXIS, Inc. Chuck Osborne Chief Financial Officer Tel: 919-544-8600 E-mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 104

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Commodity Rout Tests a Market Already Short on Nerve

Updated Category News Views 56

Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...

Continue Reading
CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 160

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 63

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 111

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 102

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 59

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 142

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading

Top 5 Most Recently Viewed Articles

Great American Media to Broadcast 2025 National Christmas Tree Lighting

Updated Category News Views 281

Great American Media to Broadcast 2025 National Christmas Tree Lighting Great American Media is proud to announce that it will serve as the exclusive broadcast home of the 2025 National Christmas Tree Lighting, a cherished event that creates a beautiful sense of community across the nation. This unique celebration, themed "Christmas as It's Meant to Be," is an opportunity...

Continue Reading
Lucent Health Data Breach: Critical Steps for Affected Individuals

Updated Category News Views 241

Overview of the Lucent Health Data Breach In the wake of a significant data breach, many individuals are left uncertain about the status of their personal information. Lucent Health Solutions, a provider in the healthcare industry, faced a considerable security incident that compromised sensitive data, affecting numerous individuals. It is essential to understand the...

Continue Reading
BofA's Optimistic Forecast for Uber Stock Sets New Target

Updated Category News Views 186

BofA's Optimistic Forecast for Uber Stock Sets New Target BofA Securities has recently provided a positive outlook for Uber Inc. (NYSE: UBER), increasing its price target for the company’s stock from $88 to $96. With a Buy rating in place, analysts highlight the upcoming earnings report slated for release on October 31, anticipating results that could slightly exceed...

Continue Reading
Endries International Welcomes New CEO Dan Crociata

Updated Category News Views 420

Endries International Welcomes New CEO Dan Crociata Endries International Inc., a renowned name in the fastener and supply chain solutions industry, has made a significant transition in its leadership. Dan Crociata, who has played a vital role within the company as Chief Financial Officer, has been appointed the Chief Executive Officer. This change marks a new chapter in...

Continue Reading
CIWA's New Internship Initiative: Building Insurance Leaders

Updated Category News Views 142

CIWA Launches Internship Program The California Insurance Wholesalers Association (CIWA) has unveiled an exciting new initiative aimed at cultivating the next generation of insurance professionals. This Internship Program is crafted to provide college students with hands-on experience in the dynamic world of excess and surplus lines insurance. Purpose of the Internship...

Continue Reading